Anticoagulant Reversal Drugs Market - Growth, Size, Share, Forecast, industry Analysis 2019 - 2027

[Credence Market Research]

Anticoagulant Reversal Drugs Market Expected To Exhibit Double Digit Growth During The Forecast Period

The latest market report published by Credence Research, Inc. “Anticoagulants Reversal Drugs Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global anticoagulants reversal drugs market expected to expand at a CAGR of 15.3% from 2018 to 2026.

Browse Full Report Originally Published by Credence Research @ https://www.credenceresearch.com/report/anticoagulant-reversal-drugs-market

Market Insights

The global market for anticoagulant reversal drugs is set to grow during the forecast period due to the approval of blockbuster drugs in recent years and the strong market-driven pipeline. The U.S. Food and Drug Administration has identified Andexxa (the most recent approved drug for factor Xa inhibitors) as an orphan drug and has been marked as an accelerated approval process. The European Medicines Agency is also in favor of granting approval for andexanet alfa, with the review of the application by the Committee for Medicinal Products for Human Use (CMPH).

Idarucizumab, licensed in 2015 for an alternative to dabigatran during atrial fibrillation, is currently undergoing clinical trials for multiple conditions such as hemorrhage and stroke. As a result, successful pipeline and government initiatives will drive the market for anticoagulant reversal drugs.  Drugs of type such as prothrombin complex concentrates, vitamin K, desmopressin, which were previously favoured for emergency containment, will see slow growth due to the release of novel drugs with better efficacy and quicker effect. Nevertheless, high proprietary drug prices will serve as a growth obstacle in emerging economies.

You can get the sample copy of this research by Credence Research here @ https://www.credenceresearch.com/sample-request/59602

In terms of geography, North America held the largest share in the global anticoagulant reversal drugs market owing to increased approvals and increasing research and development by major pharmaceutical companies in the region. Europe also a held a significant share in the global market attributable to product approvals. Growing incidence of uncontrollable bleeding episodes and usage of anticoagulants will further drive the market in the North America and Europe. U.S. emerged as the largest country level market due to efficient reimbursement scenario of for drugs, high cost of the recently approved drugs and accelerated drug approval initiative by U.S. Food and Drug Administration (FDA) to drive the market.

Asia Pacific is set to grow at fastest rate during the forecast period, driven by rising patient population for diseases such as atrial fibrillation, strokes and other cardiopulmonary diseases. Ongoing trials in the region will further stimulate the market growth in the region. The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc. and Ferring Pharmaceuticals.

Key Market Movements:

• Strong pipeline for anticoagulant reversal drugs in North America and Europe to drive the market during the forecast period
• Growing research and development by pharmaceutical players further boost market growth
• Rising incidence of uncontrollable bleeding episodes and emergency situation due to use of anticoagulants

You can get the sample copy of this research by Credence Research here @ https://www.credenceresearch.com/sample-request/59602

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.